| 1 |
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma |
Multiple Myeloma |
Drug: ABBV-383 |
TeneoOne Inc. |
Phase 1 |
NCT05650632 |
2023-03-21 |
| 2 |
Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II |
Mucopolysaccharidosis II |
Biological: Genetic HMI-203 |
Homology Medicines, Inc |
Phase 1 |
NCT05238324 |
2023-03-01 |
| 3 |
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant |
COVID-19|Coronavirus Infections |
Biological: VBI-2901e |
VBI Vaccines Inc. |
Phase 1 |
NCT05614245 |
2023-03-01 |
| 4 |
Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia |
Homozygous Familial Hypercholesterolemia |
Drug: Evinacumab |
Daniel Gaudet|Ultragenyx Pharmaceutical Inc|Ecogene 21 |
Phase 3 |
NCT05611528 |
2023-02-21 |
| 5 |
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) |
Diffuse Large B-Cell Lymphoma |
Drug: Epcoritamab|Drug: Cyclophosphamide|Drug: Rituximab|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisone |
AbbVie|Genmab |
Phase 3 |
NCT05578976 |
2023-02-08 |
| 6 |
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥0% (MK-3475-D46) |
Carcinoma, Non-Small-Cell Lung |
Biological: Sacituzumab Govitecan|Biological: Pembrolizumab |
Merck Sharp & Dohme LLC|Gilead Sciences |
Phase 3 |
NCT05609968 |
2023-02-06 |
| 7 |
A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) |
Atopic Dermatitis |
Drug: Rocatinlimab |
Amgen |
Phase 3 |
NCT05633355 |
2023-01-30 |
| 8 |
An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D |
Diabetes Mellitus|Diabetes Mellitus, Type 1|Glucose Metabolism Disorders|Metabolic Disease|Endocrine System Diseases|Autoimmune Diseases|Immune System Diseases |
Combination Product: VCTX211 |
CRISPR Therapeutics AG|ViaCyte|CRISPR Therapeutics |
Phase 1|Phase 2 |
NCT05565248 |
2023-01-20 |
| 9 |
Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam |
Spinal Muscular Atrophy |
Genetic: OAV101 |
Novartis Pharmaceuticals|Novartis |
Phase 3 |
NCT05386680 |
2023-01-12 |
| 10 |
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) |
Advanced or Metastatic Solid Tumors |
Drug: MK-6598|Biological: Pembrolizumab |
Merck Sharp & Dohme LLC |
Phase 1 |
NCT05594043 |
2022-12-21 |
이 누리집은 대한민국 공식 전자정부 누리집입니다.